Anzeige
Mehr »
Sonntag, 27.07.2025 - Börsentäglich über 12.000 News
Der Daten-Boom frisst Energie - Uran ist die Antwort!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J7EB | ISIN: FR0011341205 | Ticker-Symbol: 5NR
Tradegate
25.07.25 | 21:13
5,830 Euro
+0,87 % +0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOBIOTIX SA Chart 1 Jahr
5-Tage-Chart
NANOBIOTIX SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,6305,93026.07.
5,7205,83025.07.

Aktuelle News zur NANOBIOTIX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.07.Nanobiotix S.A. - 6-K, Report of foreign issuer1
07.07.Nanobiotix S.A.: NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)595Health authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other...
► Artikel lesen
02.07.Nanobiotix S.A. - 6-K, Report of foreign issuer1
10.06.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company10
10.06.Nanobiotix S.A. - 6-K, Report of foreign issuer2
21.05.Nanobiotix S.A. reports Q1 results4
NANOBIOTIX Aktie jetzt für 0€ handeln
21.05.Nanobiotix S.A.: Nanobiotix Provides First Quarter 2025 Operational and Financial Update174Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European...
► Artikel lesen
21.05.Nanobiotix S.A. - 6-K, Report of foreign issuer1
14.05.Nanobiotix S.A. - S-8, Securities to be offered to employees in employee benefit plans2
14.05.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company1
12.05.Nanobiotix S.A. - 6-K, Report of foreign issuer1
05.05.Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation424NEW BRUNSWICK (dpa-AFX) - Nanobiotix S.A. (NBTX), a biotechnology company focused on nanoparticle-based cancer treatments, announced Monday positive full results from the completed dose escalation...
► Artikel lesen
05.05.Nanobiotix S.A.: Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer280Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival...
► Artikel lesen
30.04.Nanobiotix S.A. - 6-K, Report of foreign issuer1
14.04.Nanobiotix S.A.: Voting Rights and Shares Capital of the Company2
10.04.Nanobiotix S.A. - 6-K, Report of foreign issuer2
04.04.Guggenheim cuts Nanobiotix stock target to $8, maintains buy5
02.04.Nanobiotix GAAP EPS of -€1.441
02.04.Nanobiotix S.A. - 20-F, Annual and transition report of foreign private issuers2
02.04.Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results148Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and...
► Artikel lesen
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1